Shinkei Therapeutics LLC

Gurpartap Singh Sachdeva

Kalpana J Patel

Suresh Borsadia

Krunal Raval

The invention is a dosing regimen for administering an aqueous composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and a second dose of amantadine hydrochloride by intravenous injection. The first dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose is administered after about four to six hours after the first dose is fully administered.

Amantadine hydrochloride for the treatment of traumatic brain injury

A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.

Growing community of inventors

Princeton Junction, NJ, United States of America

Gurpartap Singh Sachdeva